2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-116100
    (E/Z)-HA155 1229652-22-5 99.26%
    (E/Z)-HA155 is a potent autotaxin (ATX) type I inhibitor. (E/Z)-HA155 can be used for researching cancer, fibrotic diseases, inflammation, pain and angiogenesis.
    (E/Z)-HA155
  • HY-116483
    MPX-007 1688685-29-1 99.83%
    MPX-007 is a GluN2A antagonist (IC50: 27 nM). MPX-007 is a tools to probe GluN2A physiology, and to study neuropsychiatric and developmental disorders.
    MPX-007
  • HY-116548
    Nitracaine 1648893-21-3 98.9%
    Nitracaine is a structural analog of Dimethocaine (HY-121870), a local anesthetic that inhibits dopamine reuptake through the dopamine transporter.
    Nitracaine
  • HY-116594
    OPC-14523 free base 145969-30-8 98%
    OPC-14523 free base is an orally active sigma and 5-HT1A receptor agonist, with high affinity for sigma receptors (σ1/2 IC50=47/56 nM), the 5-HT1A receptor (IC50=2.3 nM), and the 5-HT transporter (IC50=80 nM). OPC-14523 free base shows antidepressant-like activity.
    OPC-14523 free base
  • HY-116663
    (±)20-HDHA 90906-41-5
    (±)20-HDHA ((±)20-HDoHE) is a racemic mixture and is an autoxidation product of Docosahexaenoic acid (DHA). (±)20-HDHA is also formed by peroxidation process in human platelets and rat brain homogenate.
    (±)20-HDHA
  • HY-116746
    Clopimozide 53179-12-7 99.63%
    Clopimozide is an orally active antischizophrenic agent that inhibits [3H]nitrendipine binding with IC50 value of 17 nM. Clopimozide is a calcium channel antagonist. Clopimozide can be used for the research of negative and positive schizophrenic symptoms.
    Clopimozide
  • HY-116753
    (-)Clausenamide 201529-58-0 99.92%
    (-)Clausenamide is an active alkaloid isolated from the leaves of Clausena lansium (Lour.) Skeels, and improves cognitive function in both normal physiological and pathological conditions. (-)Clausenamide inhibits β-amyloid (Aβ) toxicity, blocking neurofibrillary tangle formation by inhibiting the phosphorylation of tau protein. (-)Clausenamide exerts a significant neuroprotective activity against Aβ25-35. (-)Clausenamide can be used for researching Alzheimer's disease (AD).
    (-)Clausenamide
  • HY-116795
    5-Methoxy-α-ethyltryptamine 4765-10-0 98.91%
    5-Methoxy-α-ethyltryptamine is a tryptamine psychoactive substance, which has nerve stimulated effect.
    5-Methoxy-α-ethyltryptamine
  • HY-116855
    TASP0433864 1431980-60-7 99.9%
    TASP0433864 is a selective positive allosteric modulator (PAM) of metabotropic glutamate 2 (mGlu2) receptor with EC50 values of 199 nM and 206 nM against human and rat mGlu2 receptors, respectively. TASP0433864 has antipsychotic activity.
    TASP0433864
  • HY-117025
    Manzamine A 104196-68-1 98.2%
    Manzamine A, an orally active beta-carboline alkaloid, inhibits specifically GSK-3β and CDK-5 with IC50s of 10.2 μM and 1.5 μM, respectively. Manzamine A targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A has antimalarial and anticancer activities. Manzamine A also shows potent activity against HSV-1.
    Manzamine A
  • HY-117380
    SB 235375 224961-34-6 98.13%
    SB 235375 is a potent and selective antagonist of the human neurokinin-3 (hNK-3) receptor designed by optimizing the structure of 2-phenyl-4-quinolinecarboxylic acid amide. SB 235375 displays high affinity for the hNK-3 receptor, with significantly higher binding affinities than hNK-2 and hNK-1 receptors. In vitro studies demonstrated its ability to block NK-3 receptor-mediated contraction and calcium mobilization, while in vivo, SB 223412 demonstrated oral and intravenous activity against NK-3 receptor-driven responses in animal models.
    SB 235375
  • HY-117453
    BMS-901715 1699861-37-4 98%
    BMS-901715 is a potent and selective adapter protein-2 associated kinase 1 (AAK1) inhibitor with an IC50 of 3.3 nM.
    BMS-901715
  • HY-117608
    ML 315 1440251-53-5 98%
    ML 315 is a selective dual inhibitor of CDK and DYRK with IC50s of 68 nM and 282 nM, respectively. ML 315 is used in cancer and neurological disease research.
    ML 315
  • HY-117731
    UKH-1114 2113664-14-3 98%
    UKH-1114 is a potent σ2 receptor/Tmem97 agonist with a Ki value of 46 nM, showing antimechanical hypersensitivity effects. UKH-1114 alleviates mechanical hypersensitivity caused by nerve injury without any movement disorders in mice. UKH-1114 is promising for research of neuropathic pain.
    UKH-1114
  • HY-117977
    FCPR03 1917347-65-9 99.82%
    FCPR03 is a potent and selective phosphodiesterase 4 (PDE4) inhibitor with IC50 values of 60 nM, 31 nM and 47 nM for PDE4 catalytic domain, PDE4B1 and PDE4D7, respectively. FCPR03 displays at least 2100-fold selectivity over other PDEs (PDE1-3 and PDE5-11). FCPR03 has anti-inflammatory, neuroprotective and antidepressant-like effects.
    FCPR03
  • HY-118416
    BMS-986124 1447968-71-9 99.00%
    BMS-986124 is a μ-opioid receptor silent allosteric modulator (μ-SAMs). BMS-986124 antagonizes positive allosteric modulator effect of BMS-986122 (µ-OR PAM).
    BMS-986124
  • HY-119226
    VU0152099 612514-42-8 98.25%
    VU0152099 is a potent, selective and brain-penetrant mAChR M4 positive allosteric modulator with an EC50 of 0.4 µM for rat M4 receptor. VU0152099 is inactive for other mAChR subtypes or other GPCRs. VU0152099 has no agonist activity but potentiated responses of M4 to acetylcholine.
    VU0152099
  • HY-119304
    GW-406381 221148-46-5 99.69%
    GW406381, a highly selective cyclooxygenase-2 (COX-2) inhibitor, attenuates spontaneous ectopic discharge in sural nerves of rats following chronic constriction injury.
    GW-406381
  • HY-119326
    N-Formylmethamphetamine 42932-20-7 98%
    N-Formylmethamphetamine is an impurity in the synthesis of methamphetamine. N-Formylmethamphetamine is also a by-product of the Nagai reaction.
    N-Formylmethamphetamine
  • HY-119404
    Diproqualone 36518-02-2 99.9%
    diproqualone is methaqualone analogous with sedative, anxiolytic, anti-inflammatory and analgesic properties.
    Diproqualone
Cat. No. Product Name / Synonyms Application Reactivity